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Summary of article: This paper presents biopsychosocial factors associated with pain in 50 
inflammatory bowel disease. It demonstrates that emotional, cognitive and behavioural 51 
processes are associated with pain even when controlling for sociodemographic and disease-52 


























Abstract  75 
 76 
Background: Pain is frequently reported by patients with inflammatory bowel disease (IBD). 77 
Pain in IBD is not fully explained by disease activity or other clinical findings, and a recent 78 
systematic review suggested that psychosocial factors have an important role in IBD-pain. 79 
The aim of this study was to investigate psychosocial factors associated with pain in IBD.  80 
Methods: 297 adults (>16 years) with IBD were recruited from outpatient clinics (n=114) 81 
and online (n=183). Participants completed validated questionnaires assessing pain and 82 
potential emotional, cognitive and behavioural correlates. Socio-demographic and clinical 83 
factors including disease activity were also recorded. 84 
Results: 243 (81.8%) of participants reported pain. Of these 243, mean age was 36 years; 153 85 
(63%) had Crohn’s disease (CD), 90 (37%) had ulcerative colitis (UC), and 165 (67.9%) 86 
were female. 62.6% reported mild, 31.6% moderate and 5.8% severe pain. 40.3% of 87 
participants with pain met established criteria for chronic pain and 18.5% reported opioid use. 88 
Female gender, smoking, surgery and steroid use were associated with greater pain severity. 89 
Psychosocial factors associated with pain-related interference included depression, 90 
catastrophising, fear avoidance, lower self-efficacy and worse mental well-being. Regression 91 
models explained 45.6% of the variance in pain severity and 49.7% of pain interference. 92 
Psychosocial factors explained 9.5% and 24% of this variance respectively when controlling 93 
for demographic and clinical variables. 94 
Conclusions: Pain in IBD is significantly associated with cognitive and behavioural factors 95 
as well as low mood. This study contributes to a biopsychosocial understanding of pain in 96 
IBD and identifies important targets for future interventions. 97 








Pain is a common symptom in inflammatory bowel disease (IBD) and has a significant 102 
impact on quality of life1. Attenuating pain is a primary target of IBD medical management; 103 
abdominal pain severity is routinely assessed in disease activity indices in clinical practice 104 
and serves as a key endpoint in IBD clinical trials2. During active disease, over two thirds of 105 
patients report pain. However, 42-48% of patients will continue to experience pain, despite 106 
clinical and endoscopic evidence of quiescent disease3. Abdominal pain is the most 107 
commonly reported type of pain in IBD, however extra-intestinal manifestations of pain in 108 
IBD can be present in the eyes, skin or joints1,4. Pain that is not associated with inflammation, 109 
sub-acute obstruction or other disease-related complications in IBD is a clinical challenge, as 110 
conventional IBD medical therapy is inappropriate and patients report frustration that pain is 111 
not being adequately addressed5. 112 
 113 
Chronic abdominal pain in IBD is frequently categorised as irritable bowel syndrome (IBS)-114 
type symptoms. Abdominal pain is a cardinal feature of IBS, with Rome IV criteria also 115 
including altered stool frequency or stool consistency6. Thirty-six percent of people with 116 
ulcerative colitis (UC) and 46% with Crohn’s disease (CD) in remission meet the 117 
classification for IBS7, and a biopsychosocial model of IBS and IBD places these conditions 118 
on a functional continuum of gut-brain interactions8. However, there is limited evidence to 119 
confirm whether key processes and characteristics associated with chronic pain in IBS also 120 
apply to IBS-IBD populations. Many treatment approaches in IBS remain untested in the 121 
context of IBD-pain. Several key mechanisms identified in IBS and chronic pain research, 122 





behaviourally to symptoms, are yet to be explored in IBD-pain. While the primary focus of 124 
the present study was not IBS in IBD, the IBS literature informed our approach. 125 
 126 
Causes of chronic pain in IBD involve both bottom-up (visceral and peripheral) and top-127 
down (central, neurobiological and psychological) factors3. Low-grade inflammation can 128 
result in the release of cytokines and other key mediators, leading to visceral 129 
hypersensitivity9. Pain modulation in IBD is also influenced by central mechanisms; a recent 130 
small randomised controlled trial showed the ameliorating effects of transcranial direct 131 
current stimulation on several pain outcomes up to one week post treatment10. Stress and 132 
other psychological processes may exacerbate pain by disrupting descending control 133 
mechanisms, gut-brain interactions or microbial regulation, or indirectly through adopting 134 
unhelpful coping behaviours3. A recent systematic review showed a number of psychosocial 135 
factors associated with pain in IBD11, including depression, anxiety and pain catastrophising, 136 
as well as protective psychosocial factors of perceptions of social support and control, which 137 
are associated with less pain.  Coping styles and perceived stress correlated with pain in a 138 
large cohort of adults with CD12.  139 
 140 
Given this complex aetiology, adequate pain management in IBD can be challenging and 141 
there is much heterogeneity in interventions tested to date13. Chronic opioid use has been 142 
shown to increase the risk of hyperalgesia and can lead to deleterious effects on the 143 
gastrointestinal tract, including narcotic bowel syndrome and opioid-induced constipation14. 144 
Treating pain in IBD solely as a biomedical problem can limit therapeutic options and further 145 
distress patients. Adjuvant psychological support with medical management in IBD can 146 





care models in IBD encompassing psychological support have led to reductions in disease 148 
burden and healthcare costs16.  149 
 150 
Not enough is understood around potentially modifiable factors related to pain in adults with 151 
IBD. Preliminary research suggests that psychological processes have an important role in 152 
IBD-pain11,12. Many previous studies are limited by study design, including limited pain 153 
measurement; measures of pain in quality of life or disease activity indices are frequently 154 
limited to one item on pain severity. Assessing the impact of pain and pain-specific beliefs, 155 
alongside severity, provides a better understanding of chronic or functional pain in IBD17. A 156 
more detailed understanding of biopsychosocial factors associated with pain in IBD may aid 157 
the development of effective interventions3,11,18. This has been demonstrated in other 158 
gastrointestinal and autoimmune diseases, including IBS19 and pain in multiple sclerosis 159 
(MS)20.  160 
 161 
Given these considerations, the aims of this study were to i) identify the prevalence and 162 
severity of pain in adults with IBD ii) investigate the influence of sociodemographic, clinical 163 
and psychological factors in pain severity and pain-related interference in IBD. Psychosocial 164 
factors included positive and negative emotional, cognitive and behavioural factors, as well 165 











Materials and Methods 173 
Study design and population 174 
 175 
An observational cross-sectional study design was used. Data collection took place 176 
January to June 2018. The primary outcomes were pain severity and pain-related interference 177 
measured by the Brief Pain Inventory21.  178 
 179 
Inclusion criteria were diagnosis of Crohn’s disease (CD) or ulcerative colitis (UC) for more 180 
than 6 months and 16 years or older. Exclusion criteria included insufficient command of 181 
spoken English, diagnosis of indeterminate colitis and inability to provide informed consent. 182 
Participants were recruited via outpatient clinics and online; clinic participants were recruited 183 
consecutively from three National Health Service gastroenterology outpatient clinics in three 184 
London-based hospitals and online participants were recruited via the UK Crohn’s and Colitis 185 
charity website. Clinic-recruited participants had a clinician-confirmed diagnosis of CD or 186 
UC and once consented, completed a paper questionnaire in clinic or at home and then 187 
returned their questionnaire by post. Online participants provided consent and completed the 188 
questionnaire online (https://www.onlinesurveys.ac.uk/). 189 
 190 
Sociodemographic and clinical data collection 191 
 192 
The questionnaire included clinical and sociodemographic information, including IBD 193 
diagnosis, medication and smoking status, pain medication, pain-related comorbidities, 194 
strategies for pain management and classification for chronic pain. This was defined as “pain 195 
occurring every day for 3 months within the last 6 months”, which has been utilised in 196 





CD23 and Simple Clinical Colitis Activity Index (SCCAI) for UC24 was completed by a 198 
clinician or the participant in the clinic and online groups, respectively. A score of < 5 was 199 
considered as inactive disease. A stool sample was requested from clinic participants to 200 
measure faecal calprotectin, with a score of > 250ug/g used to indicate active disease25. Data 201 
on IBS and fatigue severity were collected using the IBS symptom severity score26 and IBD-202 
fatigue questionnaire (Section I)27.  203 
Study questionnaires 204 
 205 
Pain severity and Pain interference 206 
Brief Pain Inventory Short-Form (BPI) was used to assess pain severity and pain 207 
interference21. Pain severity includes 4 items, including present pain, worst pain, least level of 208 
pain and average pain severity in the previous 24 hours, yielding a mean pain severity index 209 
score. Pain interference has 7 items, assessing general activity, mood, mobility, work, 210 
relationships, sleep and enjoyment of life. A mean severity scoring of 1-3 was classified as 211 
mild pain, 4-6 moderate and 7 or more severe pain, using pre-defined cut-offs28. 212 
 213 
Depression 214 
Patient Health Questionnaire-9 (PHQ-9)29 is a self-report tool for case finding and assessing  215 
major depressive disorder. The tool assesses depressive symptoms within the last two weeks, 216 
and each item is rated on a 4-point scale reflecting the frequency of the depressive symptom 217 
(e.g. ‘never’ to ‘nearly every day’). Scores yield presentation of minimum (PHQ-9 score 0-4), 218 
mild (PHQ-9 score 5-9), moderate (PHQ-9 score 10-14), moderate to severe (PHQ-9 15-19) 219 







Generalised Anxiety Disorder-7 (GAD-7) assesses probable cases of an anxiety disorder and 223 
symptom severity and shows good reliability and validity30. Participants are asked how 224 
bothered they have been in the previous two weeks by 7 core symptoms, with response items 225 
rated 0-3 (‘not at all’ to ‘nearly every day’). The GAD-7 produces a total score of 21, with 226 
mild, moderate and severe levels of anxiety symptoms cut offs standing at ≥5, ≥10, and ≥15, 227 
respectively. 228 
  229 
Pain Catastrophising 230 
Pain Catastrophising Scale31 measures the extent to which patients ruminate, exaggerate or 231 
magnify the threat of pain sensations. It is comprised of 13-items measuring rumination, 232 
magnification and helplessness. Higher scores reflect a greater tendency to catastrophise 233 
about pain, with overall scores ranging from 0-52; 30 or more indicates clinical relevance31. 234 
 235 
Cognitive and Behavioural Response to Symptoms  236 
The Cognitive and Behavioural Response to Symptoms Questionnaire (CBRQ)32 measures 5 237 
cognitive and 2 behavioural subscales. Cognitive subscales include catastrophising, damaging 238 
beliefs, fear avoidance, embarrassment avoidance and symptom focusing. Behavioural 239 
subscales include all or nothing behaviour and avoidance/resting behaviour. As 240 
catastrophising was measured elsewhere (see above), the catastrophising scale was removed. 241 
Items are rated on a 5-point Likert-scale ranging from ‘strongly disagree’ to ‘strongly agree’. 242 
The overall score is calculated from the total of items within subscales. The CBRQ has been 243 







Perceived Stress Scale34 assesses participants’ appraisals of potential stressful situations 247 
within the previous month. Items require participants to indicate how often they have felt, for 248 
example, ‘unable to cope with all the things you had to do’. Ten items are scored on a 5-point 249 
scale, yielding an overall score of 0-40; higher scores indicate greater perceived stress, the 250 
extent to which the individual has felt overwhelmed by stressful situations within the last 251 
month.  252 
 253 
Pain self-efficacy 254 
Pain Self Efficacy Questionnaire35 assesses participants’ belief that they are able to 255 
accomplish a range of activities, despite their pain. Participants rate the 10 items on how 256 
confident they feel in their ability to carry out tasks (7-point scale; ‘not at all confident’ to 257 
‘completely confident’). For example, ‘I can still do many of the things I enjoy doing, such as 258 
hobbies or leisure activity, despite the pain’. Total scores range from 0-60, greater scores 259 
demonstrating stronger self-efficacy beliefs.  260 
 261 
Pain acceptance 262 
Chronic Pain Acceptance Questionnaire (CPAQ-8)36,37 addresses both activity engagement 263 
and ‘pain willingness’. Eight items are scored on a 6-point Likert scale from ‘never true’ to 264 
‘always true’, greater scores indicating greater acceptance of pain.  265 
 266 
Mental well-being 267 
Mental Health Continuum Short-Form (MHC-SF)38 is a 14-item measure assessing emotional 268 
(3 items), psychological (6 items) and social well-being (5 items). It demonstrates excellent 269 
internal consistency (Cronbach’s alpha >0.8). Items are rated 0-5 from ‘never’ to ‘every day’, 270 





at least one of the three signs of hedonic well-being and at least six of the eleven signs of 272 
positive functioning are considered to have ‘flourishing well-being’. ‘Languishing mental 273 
health’ is considered if an individual has answered low levels (‘never’ or ‘once or twice’) to 274 
at least one measure of hedonic well-being and at least six measures of positive functioning. 275 
Those who don’t fulfil either ‘flourishing’ or ‘languishing’ mental health are categorised as 276 
moderately mentally healthy. Higher scores represent higher levels of mental well-being. 277 
 278 
Dietary behaviour 279 
Dietary behaviour was assessed by 4 items: ‘I avoid certain food or drinks which I know 280 
makes my pain worse’; ‘I skip meals or eating to avoid worsening my pain’; ‘I tend not to eat 281 
out or eat socially because of the risk of making my pain worse’; ‘My eating patterns have 282 
changed because of my pain’. Cronbach’s alpha demonstrated that the four items have high 283 
internal consistency (α = 0.82). Items are rated from 0-4 (strongly disagree to strongly agree), 284 
and higher scores indicate greater impact of pain on dietary behaviour, with scores ranging 285 
from 0-16. 286 
 287 
Sample size 288 
According to Cohen39 to test a medium sized multiple correlation with 80% power and a 289 
significance level of 0.05, a minimum sample size of 107 participants for a regression model 290 
with eight independent variables (parameters) would be required. Adding another ten 291 
variables would increase the sample size required to about 160. A larger sample size of 292 
approximately 300 was proposed to allow for potential sub-group analyses. 293 
 294 





Missing data were replaced with imputed values using the Multiple Imputation Chained 296 
Equation Method (MICE) in Stata version 15. Overall, 15.6% of all values were missing, 297 
92.9% of the variables had at least one missing value and 93.9% of 297 participants had at 298 
least one missing value. All variables in the regression model, except for 299 
clinical/demographic variables which had no missing data and some variables with high rates 300 
of missing data (faecal calprotectin, stoma/ileo-anal pouch, and BPI item 7), were included in 301 
the imputation model.  Twenty imputed datasets were generated which exceeds the minimum 302 
of 10 based on the fraction of missing information 40. These data were transferred into SPSS 303 
for further analysis. 304 
 305 
Exploratory variables were described using frequencies, percentages, means and standard 306 
deviations. General psychological measures (depression, anxiety, stress, mental well-being) 307 
were compared between the Pain and No Pain groups using an independent two groups t-test. 308 
 309 
Multivariable regression analyses examined whether psychosocial factors predicted pain 310 
outcomes, after controlling for sociodemographic and clinical factors. Significant factors 311 
associated with pain severity or pain interference from univariate analyses were entered into a 312 
3-block multiple regression model (1: sociodemographic, 2: clinical and 3: psychological 313 
factors). Regression models were fitted to each of the 20 imputed datasets and then combined 314 
to produce averaged estimates, overall statistical tests and measures of fit (R2). 315 
 316 
To determine whether the recruitment group (clinic/online) moderated the effect of 317 
psychosocial measures on pain severity and interference, the change in fit of the regression 318 
model following the addition of the moderating effects to the overall model was tested. If the 319 





single sample with recruitment group added to the block 1 explanatory variables (see above) 321 
in the regression. 322 
 323 
The threshold for statistical significance was set at p < .05. Analyses were conducted using 324 
SPSS version 25.  325 
 326 
Ethical Considerations 327 
This cross-sectional study was approved by the London-Surrey Border Ethics Committee 328 
(17/LO/1527). All participants provided consent before taking part and were given a unique 329 
study ID to ensure anonymity. 330 
Results  331 
Descriptives 332 
 333 
A total of 297 participants completed the questionnaire; 183 CCUK-recruited online 334 
participants and 114 participants from gastroenterology outpatient clinics. 28 indicated no 335 
pain (summed score of 0 on the BPI Pain Severity) and 269 participants reported some degree 336 
of pain (90.6%). 26 participants were removed from the pain group due to incomplete data on 337 
pain-specific questionnaires, resulting in 243 participants in the pain cohort for univariate and 338 
multivariable analyses. Sociodemographic and clinical data is presented in Table 1. Of the 339 
297 participants, 181 (60.9%) had a diagnosis of CD, 190 (64%) were female and 219 340 
(73.7%) were White-British. Mean age was 36.3 years, with participants on average being 341 
diagnosed for 9 years. Mean disease activity score was 6.60 (SD= 5.42) and 4.91 (SD = 3.31) 342 
for the HBI and SCCAI, respectively. The most common IBD medication was thiopurines 343 





Insert Table 1. Socio-demographic and clinical profiles of overall cohort, clinic and online participants 345 
Participants with pain 346 
There was a significantly higher proportion of females in the group with pain (67.9% female) 347 
compared to the group with no pain (25% female). Participants with pain reported a greater 348 
number of flares in the previous 2 years and higher disease activity scores (HBI/SCCAI) 349 
compared to those reporting no pain. Mean scores and t-tests for psychological factors (non-350 
pain specific) for the pain and no-pain groups are presented in Table 2.  351 
Mean pain severity scores and other pain-related clinical data for the sample of participants 352 
with pain (n = 243) are presented in Table 3. One hundred a fifty-two (62.6%) reported mild 353 
pain, 77 (31.7%) reported moderate pain and 14 (5.8%) reported severe pain. The most 354 
common self-management strategy for pain was heat (49%), followed by exercise (32.5%). 355 
40.3% of participants reporting pain met the criteria for a chronic pain diagnosis. Abdominal 356 
pain was the most common location of pain (88.5%). Half of participants reported low back 357 
pain and 39.5% reported headache/migraines. Pain medications are presented in Table 3 with 358 
paracetamol (35.4%) and opioids (18.5%) being the most commonly used.  359 
Participants with active disease defined by the HBI or SCCAI reported significantly higher 360 
scores on pain severity in both CD and UC (p < .05). 75.2% and 75.6% of participants with 361 
CD and UC, respectively, scored at least moderate IBS symptom severity. Of the 43 362 
participants with pain who provided a stool sample for faecal calprotectin, 27.9% with 363 
quiescent disease reported at least moderate pain. 364 
Overall 27.6% showed ‘languishing’ mental well-being, 31.3% showed ‘flourishing’ mental-365 
health and 41.2% were moderately mentally healthy. 366 





Differences were identified between participants recruited via the clinic or online. Disease 368 
duration was significantly longer in the clinic compared to the online group (12.5 vs. 8.3 369 
years, p=.001). Number of self-reported flares in the prior 2 years (3.5 vs. 2.4, p<.001) and 370 
self-reported disease activity scores (HBI: 8.1 vs. 3.5, p<.001; SCCA: 5.8 vs. 3.7, p<.001) 371 
were significantly higher in the online participant group. Significantly more participants in 372 
the online cohort were female (71.0% vs. 52.6%, p=.001) and were of White British origin 373 
(82.0% vs. 60.5%, p<.001). 374 
Participants recruited online reported significantly higher scores than clinic recruits for pain 375 
severity (3.7 vs. 2.7, p = <.001), pain interference (4.4 vs. 3.4, p = .012) and negative 376 
psychosocial variables (Supplementary Table 1). A significantly greater proportion of online 377 
than clinic participants were on anti-depressants (24.0% vs.13.2%, p=.030), met the 378 
classification for chronic pain (48.5% vs. 24.4%, p<.001) and listed co-codamol as their pain 379 
medication (17.4% vs. 3.7%, p=.002). Of the online participants with pain, 8.7% and 4.0% of 380 
the online cohort had a current stoma or ileo-anal pouch, respectively. There were insufficient 381 
data due to missingness to analyse clinic participants with stomas/ileo-anal pouch.  382 
Insert Table 2. Means and standard deviations of pain and general psychological factors in pain and non-383 
pain cohort 384 
Insert Table 3. Pain-related characteristics of overall, clinic and online pain cohort  385 
 386 
Univariate analyses  387 
Univariate analyses of sociodemographic and clinical factors associated with pain are 388 
presented in Supplementary Tables S2-4. Greater pain severity scores were associated with 389 
female gender and previous surgery. Anti-depressant use was significantly associated with 390 





severity and interference. Azathioprine and methotrexate were significantly associated with 392 
greater pain interference. No other IBD medication was significantly associated with pain 393 
outcomes. Current smoking, employment and education status were all significantly 394 
associated with pain outcomes (p < .05). Higher educational attainment and being employed 395 
was associated with less pain severity. Dummy variables were created for low educational 396 
attainment and unemployed or retired for multivariable analyses. Fatigue significantly 397 
correlated with pain severity (r = 0.49) and pain interference (r = 0.42).  398 
Pearson correlations of psychosocial factors associated with pain are presented in 399 
Supplementary Table S4. Pain severity significantly correlated with all psychological factors. 400 
Pain interference significantly correlated with all psychological factors, excluding pain 401 
acceptance. Greater pain severity and interference were associated with greater impact on 402 
dietary behaviour (r = 0.32 and r = 0.39, respectively).  403 
Multivariable analyses  404 
Collinearity diagnostics revealed significant intercorrelations between some independent 405 
regression variables. The final set of independent variables selected for multivariate analyses 406 
did not violate multi-collinearity assumptions (VIF <2, condition index < 30). 407 
The addition of the six moderators (effect of recruitment group on the relationship between 408 
psycho-social factors and pain) did not improve the fit of either model. In both cases the F-409 
test was not statistically significant (Pain severity: F[6, 201]=1.16, p=.39, pain interference: 410 
F[6, 201]=1.23, p=.29). Changes in the R2 were small (Pain severity: 45.6% to 47.4% 411 
Δ=1.8%, Pain interference: 49.7% to 51.5% Δ=1.8%). A decision was therefore taken to drop 412 





Multivariable analyses of pain severity and pain interference are presented in Tables 4 and 5 414 
respectively.  415 
For pain severity the addition of psychosocial factors to the regression model containing 416 
sociodemographic and clinical factors was statistically significant F(18, 225) = 9.429, p < 417 
.001. Sociodemographic factors explained 17.6% of the variance in pain severity in the 418 
overall model. Clinical factors explained an additional 17.9% and psychosocial factors 419 
explained a further 9.5% of the variance in pain severity. The overall model explained 45.6% 420 
of the variance in pain severity. 421 
For pain interference, the addition of psychosocial factors to the model was statistically 422 
significant F(18, 225) = 11.110, p < .001. Socio-demographic factors explained 8.9% of the 423 
variance in pain interference, and clinical factors explained an additional 16.2% of the 424 
variance. Psychological factors explained a further 24% of the variance in pain interference. 425 
The overall model explained 49.7% of the variance in pain interference.  426 
Table 4 Multivariable regression analyses of socio-demographic, clinical and psychological factors 427 
predicting pain severity in pain cohort (n=243) 428 
Table 5. Multivariable regression analyses of socio-demographic, clinical and psychological factors 429 
predicting pain interference in pain cohort (n=243) 430 
 431 
Discussion 432 
This study aimed to develop a better biopsychosocial understanding of pain in adults with 433 
IBD. Results demonstrate that pain is a prevalent problem and that emotional, cognitive and 434 
behavioural processes are associated with pain in addition to demographic and disease 435 
processes (findings summarised in Figure 1). Psychosocial processes explained an additional 436 





elimination of pain may not be possible due to the relapsing remitting nature of IBD, 438 
targeting potentially modifiable psychological factors related to pain severity and interference 439 
may be of value to improve functioning and quality of life.  440 
Over a third of participants with pain reported at least moderate pain severity, and a 441 
substantial number of participants had chronic pain and were on anti-depressants. Previous 442 
use of the BPI in an IBD population has shown similar distributions for mild, moderate and 443 
severe pain28, however a lower proportion of individuals in this study reported no pain 444 
(9.4%). After paracetamol, opioids were the most frequently listed medication for pain, used 445 
by 18.5% of individuals with pain. This supports increasing trends of opioid prescription 446 
evident in non-cancer pain in the UK41. Research demonstrates the adverse effects of 447 
prolonged opioid use in IBD, including dose-dependent effects on morbidity and mortality 448 
and greater healthcare utilisation42. In a US study of Crohn’s disease (CD), 37% of patients 449 
diagnosed with concomitant functional symptoms were misusing opioid medication, 450 
measured by a prescription monitoring programme43. Clearer defined prescribing criteria for 451 
clinicians and greater awareness and support for patients are vital to reduce use of opioids in 452 
IBD. 453 
Emotional factors including depression and anxiety were associated with increased pain 454 
severity and interference. Pain is likely a distressing experience for people with IBD. In turn, 455 
a top-down affective dimension in pain processing may create a vicious cycle of pain and 456 
distress 3. Although acute stress has a role in buffering noxious input (facilitating a ‘fight or 457 
flight’ response), chronic stress, worrying and hypervigilance may disrupt descending 458 
inhibitory control mechanisms, enhancing the experience of pain3. A bi-directional 459 
association between depression and visceral pain in IBD may be explained by dysregulated 460 





psychosocial stressors is another recognised mechanism explaining the interaction between 462 
persistent inflammation and depression45.  463 
To our knowledge, this is the first study in IBD to show an association between pain and 464 
certain positive psychological constructs, namely pain self-efficacy and psychological well-465 
being. Alongside identifying psychosocial risk factors that are anticipated to exacerbate 466 
pathology, understanding positive psychological processes may be of equal value in the aim 467 
of preventing or reducing pain-related distress and disability46. Self-efficacy, defined as an 468 
individual’s perceived ability to carry out behaviours to meet a goal or outcome47, is a widely 469 
empirically-supported mechanism in the context of adopting new health behaviours, adjusting 470 
beliefs or engaging in helpful coping strategies. It has been associated with less impairment 471 
and distress in chronic pain48, and improved outcomes in adult and child IBD populations49-472 
51. Greater psychological well-being or optimism may be another important construct in 473 
increasing one’s likelihood of engaging in helpful coping strategies. In support, levels of 474 
gratitude in IBD have significantly predicted lower depression in a longitudinal study52. 475 
These positive psychological factors may serve as ‘resilience mechanisms’ facilitating 476 
adjustment in chronic illness and buffer the impact of symptoms53. Understanding both risk 477 
factors and resilience factors in IBD may help to identify patients who exhibit ‘low 478 
resilience’ and may be more likely to develop functional symptoms46. Self-efficacy and 479 
psychological well-being, among other positive psychological constructs, can be targeted in 480 
interventions through building of self- confidence, control and self-management skills.  481 
An association between greater pain and fear avoidance and catastrophising about pain 482 
echoes findings in previous IBD studies11, with the latter shown to predict functional 483 
disability in adolescents with IBD54. Other cognitive-behavioural responses to symptoms 484 





symptoms are sign of damage, all or nothing and avoidance-resting behaviours in response to 486 
symptoms, which have not previously been investigated in IBD-pain populations. It is 487 
thought that avoidant thoughts and behaviours may lead to the development of chronic pain 488 
by an increasing fear of movements and inactivity, leading to disability, lethargy and low 489 
mood55. All or nothing behaviours refer to cyclical periods of intense activity when feeling 490 
well, leading to burn-out, over-exhaustion and prolonged periods of rest. Setting realistic 491 
goals for daily activity rather than being governed by symptoms may be a helpful strategy, 492 
such as through graded activity and exposure techniques. Identification of pain-specific 493 
cognitive and behavioural processes in this study builds on a biopsychosocial understanding 494 
of IBD-pain and further identifies important treatment targets for future pain management 495 
interventions in IBD.  496 
The lack of association between pain acceptance and outcomes is inconsistent with previous 497 
research. Pain acceptance has shown significant associations with resilience and less negative 498 
mood in chronic IBD-pain populations56. Illness acceptance has been shown to predict 499 
personal growth, relationship satisfaction and life satisfaction57. Mindfulness interventions, of 500 
which acceptance is a key tenant, have shown positive outcomes in IBD-patients with 501 
functional abdominal symptoms58. A lack of an association in this study may be explained by 502 
the use of a chronic pain acceptance questionnaire with a sample who did not all meet chronic 503 
pain criteria. Alternatively, it may be that pain acceptance is more strongly associated with 504 
improvements in mood and quality of life rather than influencing pain outcomes directly. 505 
Both pain and illness acceptance warrant further investigation in IBD.  506 
Female gender, current smoking status and steroid use were significantly associated with pain 507 
outcomes, consistent with previous research11. Moreover, the study demonstrated 508 





This suggests that the online community may be particularly vulnerable and a key target sub-510 
population for an intervention. Recently, a meta-analysis examined the differences in CBT 511 
trial results in individuals recruited in clinical services compared to open community 512 
recruitment, where participants self-refer to take part in studies59. In 53 comparisons of 513 
internet-based CBT versus waitlist control, open community recruited populations 514 
demonstrated greater reductions in anxiety symptoms, which were partly explained by greater 515 
treatment adherence and stricter exclusion of severe depression in open community groups. 516 
This, and our study findings, suggest that online self-referring individuals may be more likely 517 
to present higher pain and distress, and possibly engage and benefit more from psychological 518 
interventions. However, recruiting from an online source only may limit generalisability to a 519 
‘clinical’ population.  520 
Significant associations between disease activity and pain suggests that disease management 521 
should remain a key therapeutic target when pain is reported. However, the use of self-522 
reported indices to measure disease activity in this study may be conflated by affective 523 
distress. A recent study showed that 29% of IBD patients with histological and colonoscopy-524 
confirmed quiescent disease were erroneously classified as having active disease through the 525 
use of HBI/SCCAI, and fulfilled for Rome III criteria for IBS60. Faecal calprotectin was not 526 
associated with pain in a sub-set of participants in this study, further highlighting the complex 527 
relationship between symptom reporting and pathophysiology in IBD. Inconsistencies 528 
between clinical and endoscopic biomarkers of both pain and disease activity in IBD have 529 
been highlighted previously3 and support the use of objective and subjective markers, as well 530 
as validated patient report outcomes, to guide clinical decision-making.  531 
An impact of pain on dietary behaviours identified in this study aligns with other work in 532 





behaviour61. Future studies could explore whether regulating eating behaviours and assisting 534 
with smoking cessation helps to improve pain outcomes. Similarly, withdrawal from opioids 535 
could be considered.  Pain was also associated with IBS severity scores and fatigue, 536 
reinforcing an overlap in symptomology8 and symptom clustering in IBD62.    537 
The results of this study echo psychological processes identified in IBS and pain associated 538 
with other long-term conditions. Gastrointestinal-specific anxiety and illness cognitions have 539 
been identified as key mechanisms of treatment in IBS63; one study examining the effects of a 540 
brief cognitive behavioural therapy (CBT) intervention found a significant decrease in 541 
catastrophising, damaging beliefs and fear avoidance measured by the CBRQ64. Distress, 542 
catastrophising and fear avoidance were significantly associated with pain severity and 543 
interference in MS-pain20. Similar findings in this study suggest that addressing emotions and 544 
pain-specific cognitions and behaviours may be important in reducing pain severity and 545 
impact in IBD. These processes underpin techniques used in CBT. CBT has a good evidence 546 
base in IBS65,66 and chronic pain67 and growing evidence base in IBD, showing 547 
improvements in quality of life and other psychological outcomes68,69. 548 
There are several limitations in this study. Firstly, self-reported disease activity was measured 549 
for the online cohort, and this group of individuals may have been self-selecting with pain, 550 
whereas participants in clinic were approached consecutively. This may explain the higher 551 
scores for disease activity, pain and psychological factors in the online group. Although this 552 
study aimed to provide an objective measure of disease activity in clinic-recruited 553 
participants, only a small sub-set of participants returned samples, therefore faecal 554 
calprotectin levels were not included in the multivariable analysis. This study did not measure 555 





markers. Finally, the cross-sectional nature of the study limits conclusions regarding the 557 
direction of causality between pain and psychological factors.  558 
Future research on pain in IBD should assess pain severity, disability and pain-related beliefs 559 
using validated pain tools. Studies of longitudinal design should aim to examine the effects of 560 
psychological factors on pain severity and impact over time. Inclusion of objective markers 561 
of disease activity and other physiological markers of pain can strengthen further studies in 562 
understanding the interaction between psychological, central and peripheral processes. 563 
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Table 1. Socio-demographic and clinical profiles of the total sample (n=297) 
Patient characteristics n (%) 
IBD diagnosis (CD/UC) 181/116 (60.9/39.1) 
Gender (Female/Male) 190/107 (64.0/36.0) 
Ethnicity  
White-British 219 (73.7) 
Education  
No formal qualifications 11 (3.7) 
Vocational qualifications 17 (5.7) 
School qualifications 37 (12.5) 
Advanced school qualifications 45 (15.2) 
University degree 111 (37.4) 
Postgraduate degree 70 (23.6) 
Marital status  
Married/civil partnership/living with 
partner 
132 (46.3) 
Divorced/separated 35 (11.8) 
Single 116 (39.1) 
Employment status   
Employed full-time 161 (54.2) 
Employed part-time 44 (14.8) 
Full or part-time education 37 (12.5) 
Full-time domestic responsibilities 9 (3.0) 
Retired 19 (6.4) 
Unemployed 20 (6.7) 
Smoking status  
Current smoker 33 (11.1) 
Previous smoker 64 (21.5) 
Non-smoker 198 (66.7) 
Current anti-depressant use 59 (19.9) 
Previous surgery  93 (31.3) 
IBD medication  
Sulfasalazine 6 (2.0) 
5-ASA 96 (32.3) 
Azathioprine 98 (33.0) 
Mecaptapurine  16 (5.3) 
Methotrexate 10 (3.4) 
Infliximab 25 (8.4) 
Adalimumab 52 (17.5) 
Vedolizumab 18 (6.1) 
Prednisolone 32 (10.8) 
Budesonside 13 (4.4) 
Allopurinol 11 (3.7) 
 Mean (SD) 
Age (yrs) 36.03 (12.71) 
Disease duration (yrs) 9.62 (9.93) 
No. of flares in prior 2 years 3.04 (2.21) 
Disease activity score   
HBI  6.60 (5.42) 





Table 2. Means and standard deviations of general psychological and pain factors in the pain and non-
pain cohorts 
 Pain Cohort 
No Pain 
Cohort   




General psychosocial measures Mean (SD) Mean (SD) Mean difference, 95% CI, p 
Depression 10.66 (6.97) 4.36 (5.86) 6.3 -8.98 to -3.62, p<.001* 
Anxiety  8.28 (5.91) 4.27 (5.26) 4.01, -6.30 to -1.71, p=.001* 
Stress  22.88 (7.82) 15.93 (6.37) 6.95, -9.92 to -3.90, p<.001* 
Mental well-being  39.11 (15.97) 45.18 (16.14) -6.07, -0.01 to 12.53, p=.050 
  
  
Pain-specific measures  
  
Pain self-efficacy 32.67 (15.65) 
  
Pain catastrophizing 18.58 (13.06) 
  
Pain fear avoidance 12.12 (5.41) 
  
Symptom focusing 12.79 (5.89) 
  
Embarrassment avoidance 10.44 (6.90) 
  
All or nothing behaviour 9.78 (5.47) 
  
Avoidance resting behaviour 13.32 (7.26) 
  
Pain acceptance 27.16 (5.06) 
  






Table 3. Pain-related characteristics of overall pain cohort (n = 243) 
Pain-related factors N (%) 
Pain Severity (mean, SD) 3.33 (1.96) 
Pain Interference (mean, SD) 4.06 (2.92) 
No. of Pain Locations 3.52 
Pain severity rating:  
Mild 152 (62.6) 
Moderate  77 (31.7) 
Severe 14 (5.8) 
Chronic Pain Diagnosis 98 (40.3) 
Pain Medications:  
Paracetamol 86 (35.4) 
Co-codamol 31 (12.8) 
Opioid 45 (18.5) 
Antispasmodic 12 (4.9) 
NSAIDs 11 (4.5) 
Pregabalin/Gabapentin 7 (2.9) 
Pain-related conditions:  
Low back pain 122 (50.0) 
Migraine/Headache 96 (39.5) 
Arthritis 51 (21.4) 






Table 4 Multivariable regression analyses of socio-demographic, clinical and psychological factors predicting pain severity in pain cohort (n=243) 
Pain Severity Block 
1 
  Block 
2 
   Block 3  
 B** 95% CI ∆R






Low Educational Attainment* 
Current smoker 



















































































































































































Table 5. Multivariable regression analyses of socio-demographic, clinical and psychological factors predicting pain-related interference in pain cohort (n=243) 
 
Pain-related interference Block 1   Block 2   Block 3   
 B** 95% CI ∆R





























































































































































































Figure 1. What does this study add? 
 
What do we know already?  
• Pain is a common symptom of IBD  
• Over a third of people with IBD continue to report pain in remission, defined by clinical and endoscopic 
markers  
• Pain is understood as a biopsychosocial problem, involving neurobiological, peripheral factors and central 
factors 
What does this study add?  
• Many patients experience pain which is chronic and report the use of opioids and anti-depressants 
• Emotions, cognitions and behaviours are significantly associated with pain severity and pain-related 
interference in IBD, including pain-specific cognitions and behaviours 
• Positive psychological factors, namely pain self-efficacy and positive psychological well-being, are associated 
with less pain 
• Results suggest that addressing emotions and pain-related cognitions and behaviours are important treatment 
targets for future pain management interventions in IBD 
 
